Company: SMNR
Filing Date: 2025-07-23
Form Type: S-4/A
Source: 0001193125-25-163401
Chunk: 4

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-23
Form: S-4/A
Chunk 4
---
 A ordinary shares, par value $0.0001 per share, of Denali (“Denali Class A Ordinary Shares”) and holders of Class B ordinary shares, par value $0.0001 per share, of Denali (“Denali Class B Ordinary Shares”), voting together as a single class, will be asked to approve and adopt the Agreement and Plan of Merger, dated as of August 30, 2024 (as it may be amended or restated from time to time in accordance with its terms, including by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 16, 2025, (“Amendment No. 1 to Merger Agreement”) and Amendment No. 2 to Agreement and Plan of Merger, dated as of July 22, 2025, (“Amendment No. 2 to Merger Agreement”), the “Merger Agreement”), by and among Denali, Denali Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Denali (the “Merger Sub”), and Semnur Pharmaceuticals, Inc., a Delaware corporation (“Semnur”) and a majority owned subsidiary of Scilex Holding Company (“Scilex”), and the other related proposals described in the proxy statement/prospectus. Copies of the Merger Agreement, Amendment No. 1 to Merger Agreement and Amendment No. 2 to Merger Agreement are attached to this proxy statement/prospectus as Annex A-1, Annex A-2 and Annex A-3, respectively.

Pursuant to the Merger Agreement, subject to the terms and conditions set forth therein, (i) prior to the Effective Time (as defined in the proxy statement/prospectus), Denali will change its jurisdiction of incorporation by deregistering as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware (the “Domestication”) and (ii) at the Effective Time, and following the Domestication, Merger Sub will merge with and into Semnur (the “Business Combination”), with Semnur continuing as the surviving entity and a wholly owned subsidiary of Denali. In connection with the consummation of the Business Combination, Denali will be renamed as “Semnur Pharmaceuticals, Inc.” and Semnur will be renamed as Semnur, Inc. In this document, we use the term “New Semnur” to refer to Denali after completion of the transactions